Category: Regions

Nektar and BMS End Clinical Development of Bempegaldesleukin in Combination with Opdivo
April 15, 2022 Off

Nektar and BMS End Clinical Development of Bempegaldesleukin in Combination with Opdivo

By Author

Nektar Therapeutics (NASDAQ: NKTR) and Bristol Myers Squibb (NYSE: BMY) have announced that based on results from pre-planned analyses of two late-stage clinical studies of bempegaldesleukin (BEMPEG) in combination with Opdivo (nivolumab) in renal cell carcinoma (RCC) and bladder cancer, the companies have jointly decided to end the global clinical development program for bempegaldesleukin in combination with Opdivo.

Valneva’s Inactivated Covid-19 Vaccine Gets CMA in UK
April 14, 2022 Off

Valneva’s Inactivated Covid-19 Vaccine Gets CMA in UK

By Author

The Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom has granted Conditional Marketing Authorization (CMA) for Valneva’s inactivated whole-virus COVID-19 vaccine candidate, VLA2001, for primary immunization in adults 18 to 50 years of age.

EC Approves Astellas-Seagen’s Locally Advanced or Metastatic Urothelial Cancer Drug
April 13, 2022 Off

EC Approves Astellas-Seagen’s Locally Advanced or Metastatic Urothelial Cancer Drug

By Author

Astellas Pharma Inc. and Seagen Inc. (Nasdaq:SGEN) have announced that the European Commission (EC) has approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The EC approval is supported by data from the global phase 3 EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.